Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on ADMA Biologics and increased the price target from $6.5 to $8.
February 29, 2024 | 6:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on ADMA Biologics and raised the price target from $6.5 to $8.
The increase in price target by a reputable analyst firm like Cantor Fitzgerald suggests a positive outlook on ADMA Biologics' stock. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100